Latifolin protects against myocardial infarction by alleviating myocardial inflammatory via the HIF-1α/NF-κB/IL-6 pathway

Abstract

Context: The Traditional Chinese herb medicine Dalbergia odorifera T. Chen (Fabaceae), exerted a protective effect on myocardial ischaemia. Latifolin is a neoflavonoid extracted from Dalbergia odorifera. It has been reported to have the effects of anti-inflammation and cardiomyocyte protection. Objective: To investigate whether latifolin can improve myocardial infarction (MI) through attenuating myocardial inflammatory and to explore its possible mechanisms. Materials and methods: Left coronary artery was ligated to induce a rat model of MI, and the rats were treated with sodium carboxymethyl cellulose (CMC-Na) or different doses of latifolin (25, 50, 100 mg/kg/d) by oral gavage for 28 days. Serum contents of myocardial enzyme were measured at seven and fourteen days after treatment. Cardiac function, infarct size, histopathological changes and inflammatory cells infiltration was assessed at 28 days after treatment. Western blotting was used to investigate the underlying mechanisms. Results: Latifolin treatment markedly decreased the contents of myocardial enzymes, and increased left ventricular ejection fraction (85.27% vs. 59.11%) and left ventricular fractional shortening (62.71% vs. 45.53%). Latifolin was found to significantly reduced infarction size (27.78% vs. 39.07%), myocardial fibrosis and the numbers of macrophage infiltration (436 cells/mm 2 vs. 690 cells/mm 2). In addition, latifolin down-regulated the expression levels of hypoxia-inducible factor-1a (0.95-fold), phospho-nuclear factor-jB (0.2-fold) and interleukin-6 (1.11-fold). Discussion and conclusions: Latifolin can protect against myocardial infarction by improving myocardial inflammation through the HIF-1a/NF-jB/IL-6 signalling pathway. Accordingly, latifolin may be a promising drug for pharmacological treatment of ischaemic cardiovascular disease.

Delivery of astragalus polysaccharide by ultrasound microbubbles attenuate doxorubicin-induced cardiomyopathy in rodent animals

“…Previous reports have shown that NF-κB, as a key factor in regulating signaling pathway closely related to systemic inflammatory reactions inflammatory, participated in the transcription and modulation of many inflammatory mediators [ 36 ]. Reports have shown that the release of IL-1β and TNF-α, which could be promoted by activated NF-κB activation, stimulated the production of inflammatory factors then resulted in excessive hypertrophy of cardiomyocytes, and finally irreversible damage to myocardial tissue fibrosis [ 37 ]. In this study, we further found that long-term treatment of APS can significantly reduce the expression of all tested pro-inflammatory markers that lead to a notable reduction of inflammatory response in myocardial tissue, thereby significantly reducing the occurrence of inflammatory response, and has a significant advantage over APS alone.…”

Potential Targets and Mechanisms of Dalbergia odorifera on Treating Lung Adenocarcinoma Explored by Network Pharmacology

“…Besides, the volatile oil of DO increased the absorbance of major ingredients in QSYQ 33 . Recently, latifolin, as a newly extracted flavonoid, was shown to protect against myocardial infarction and oxidative stress-induced senescence 34,35 36 . Hydroxyobtustyrene, a cinnamyl phenol, exerted an anti-hypoxia effect on neuronal cells 37 .…”

Cytokine storm: behind the scenes of the collateral circulation after acute myocardial infarction

“…For example, latifolin and astragaloside IV can regulate expression of NF-κB. The former inhibits the inflammatory response of macrophages by regulating the HIF-1α/NF-κB/IL-6 signaling pathway, and the latter regulates TLR4/NF-κB/PPAR signaling-mediated energy biosynthesis to alleviate LPS-induced myocardial injury [ 119 , 120 ]. In addition, morroniside, NR4A3 and metformin can suppress expression of NF-κB.…”